A method and engineering strain for increasing the yield of synthetic L-isoleucine based on methylmalate pathway
By overexpressing methylmalate synthase and transporter in E. coli and combining expression-related enzymes, the problems of low efficiency of the threonine pathway and insufficient production of the methylmalate pathway are solved, and L-isoleucine is significantly improved synthesis capability and efficiency.
Patent Information
- Application Number
- CN202411365012.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-29
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-09-29
AI Technical Summary
In the prior art, the efficiency of using the threonine pathway to produce L-isoleucine is low, and the methylmalic pathway cannot enter the cell due to the inhibitory effect of carbon metabolism in the presence of glucose, resulting in the production of extracellular methylmalic acid. reduce.
The methylmalate synthase gene is overexpressed in E. coli and the carboxylic acid transporters DcuD, DauA or DcuA are expressed, and the methylmalate pathway-related enzymes are further expressed to improve the synthesis ability of L-isoleucine.
The L-isoleucine synthesis ability based on the methylmalic acid pathway has been significantly improved, and the inhibitory effect of glucose on the utilization of methylmalic acid has been relieved, thereby improving yield and efficiency.
Smart Images

Figure CN118853722B_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of engineering strains, and in particular to a method and an engineering strain for increasing the yield of synthetic L-isoleucine based on a methylmalate pathway. Background Art
[0002] L-isoleucine is a branched-chain amino acid and is the raw material for the synthesis of many important substances such as hormones and enzymes in humans and animals. As one of the essential amino acids, L-isoleucine cannot be synthesized by humans and most livestock and poultry animals themselves, so it has huge market demand in the fields of feed, food, medicine and health care.
[0003] Compared with traditional methods, microbial fermentation is the main method for producing L-isoleucine on an industrial scale due to its low production cost and environmentally friendly fermentation conditions. At present, the production of L-isoleucine by fermentation mainly relies on the threonine pathway, in which threonine is used as a precursor to synthesize α-ketobutyric acid, an important intermediate in the synthesis of L-isoleucine. The threonine pathway is the main L-isoleucine synthesis pathway for most microorganisms. However, the synthesis steps of this pathway are lengthy, and there are complex metabolic regulation mechanisms, which makes the L-isoleucine synthesis efficiency that relies on the threonine pathway low. In order to develop high-performance L-isoleucine production strains, researchers have carried out a lot of work through mutagenesis breeding and rational metabolic engineering transformation, but due to the complexity of the synthesis pathway and regulation, the overall improvement is limited.
[0004] In addition to the threonine pathway, there are many L-isoleucine biosynthetic pathways in nature, among which the methylmalate pathway (also known as the pyruvate pathway) is one of the most studied. In this pathway, the production of α-ketobutyrate starts with the synthesis of methylmalate from pyruvate and acetyl-CoA. Compared with the threonine pathway, the total synthesis steps of isoleucine synthesized through the methylmalate pathway are 5 steps less and the feedback inhibition sites are 3 less. It can be seen that the methylmalate pathway has shorter synthesis steps and a simpler regulation mode, and is a very potential L-isoleucine biosynthetic pathway. However, when the engineered strain that produces L-isoleucine using the methylmalate pathway (also known as the pyruvate pathway) is fermented in a medium with glucose as the carbon source, a large amount of methylmalate will be produced. The strain itself will quickly excrete the excessive methylmalate to the extracellular space. In the presence of glucose, the extracellular methylmalate can no longer enter the cell for metabolism due to the inhibition of carbon metabolism, resulting in the accumulation of extracellular methylmalate, and the efficiency of synthesizing L-isoleucine using the methylmalate pathway is reduced. Summary of the invention
[0005] The purpose of the present invention is to provide a method for increasing the yield of synthetic L-isoleucine based on methylmalate pathway.
[0006] Another object of the present invention is to provide an engineered strain for synthesizing L-isoleucine based on the methylmalate pathway.
[0007] The method for increasing the yield of synthetic L-isoleucine based on the methylmalate pathway according to the present invention comprises the following steps:
[0008] Overexpression of methylmalate synthase gene in Escherichia coli;
[0009] Expressing carboxylic acid transporter DcuD, DauA or DcuA encoding gene, wherein the amino acid sequences of the carboxylic acid transporter DcuD, DauA and DcuA are shown as SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively.
[0010] According to the method for increasing the yield of synthesized L-isoleucine based on the methylmalate pathway of the present invention, the amino acid sequence of methylmalate synthase is shown as SEQ ID NO.5.
[0011] According to the method for increasing the yield of synthesized L-isoleucine based on the methylmalate pathway of the present invention, the nucleotide sequence of the methylmalate synthase gene is shown in SEQ ID NO:6.
[0012] According to the method for increasing the yield of synthesized L-isoleucine based on the methylmalate pathway of the present invention, the method further comprises the step of expressing a gene encoding an enzyme related to the methylmalate pathway in Escherichia coli, wherein the enzyme related to the methylmalate pathway comprises one or more of the following enzymes:
[0013] Isopropylmalate isomerase (IPMI), 3-isopropylmalate dehydrogenase (IPMD), acetohydroxyacid synthase (AHAS), acetohydroxyacid reductoisomerase (AHAIR), dihydroxyacid dehydratase (DHAD), branched-chain amino acid aminotransferase (BCAT), leucine dehydrogenase (LeuDH), and valine dehydrogenase (ValDH).
[0014] Wherein, the isopropylmalate isomerase includes isopropylmalate isomerase IPMI or isopropylmalate isomerase LeuCD, wherein the isopropylmalate isomerase LeuCD includes a LeuC subunit and a LeuD subunit;
[0015] The 3-isopropylmalate dehydrogenase includes 3-isopropylmalate dehydrogenase IPMD or 3-isopropylmalate dehydrogenase LeuB;
[0016] The acetohydroxyacid synthase includes acetohydroxyacid synthase AHAS or acetohydroxyacid synthase IlvIH;
[0017] The acetohydroxy acid reductoisomerase includes acetohydroxy acid reductoisomerase AHAIR or acetohydroxy acid reductoisomerase IlvC;
[0018] The dihydroxy-acid dehydratase comprises dihydroxy-acid dehydratase DHAD or dihydroxy-acid dehydratase IlvD;
[0019] The branched-chain amino acid aminotransferase includes dihydroxyacid dehydratase BCAT or dihydroxyacid dehydratase IlvE;
[0020] The leucine dehydrogenase includes a subunit LeuD and a subunit LeuH.
[0021] According to a specific embodiment of the present invention, LeuC, its amino acid sequence is shown in SEQ ID NO: 7; LeuD, its amino acid sequence is shown in SEQ ID NO: 8; LeuB, its amino acid sequence is shown in SEQ ID NO: 9; IlvI, its amino acid sequence is shown in SEQ ID NO: 10; IlvH, its amino acid sequence is shown in SEQ ID NO: 11; IlvC, its amino acid sequence is shown in SEQ ID NO: 12; IlvD, its amino acid sequence is shown in SEQ ID NO: 13; IlvE, its amino acid sequence is shown in SEQ ID NO: 14.
[0022] According to the engineered strain for synthesizing L-isoleucine based on the methylmalate pathway of the present invention, the engineered strain is an Escherichia coli strain obtained by the following transformations:
[0023] Overexpression of methylmalate synthase gene;
[0024] Expressing carboxylic acid transporter DcuD, DauA or DcuA encoding gene, wherein the amino acid sequences of the carboxylic acid transporter DcuD, DauA and DcuA are shown as SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively.
[0025] Advantages of the technical solution of the present invention:
[0026] The engineered strain that produces L-isoleucine using the methylmalate pathway (also known as the pyruvate pathway) will produce a large amount of methylmalate when fermented in a medium with glucose as a carbon source. The strain itself will quickly excrete the excessive methylmalate to the outside of the cell. In the presence of glucose, the extracellular methylmalate cannot enter the cell for metabolism due to the carbon metabolism inhibition effect, thereby causing the accumulation of extracellular methylmalate and reducing the efficiency of synthesizing L-isoleucine using the methylmalate pathway. The present invention determines that the carboxylate transporters DcuD, DauA, and DcuA have the function of methylmalate absorption proteins, which can effectively relieve the inhibitory effect of glucose on the utilization of methylmalate during fermentation of the engineered strain, and significantly improve the L-isoleucine synthesis capacity based on the methylmalate pathway. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 A comparison of isoleucine biosynthetic pathways based on the threonine pathway and the methylmalate pathway is shown;
[0028] Figure 2 The results of shake flask fermentation of the starting strain BW25113 and the engineered strains BW1 and BW2 provided in Example 1 of the present invention in M9+Glu medium are shown;
[0029] Figure 3 The results of shake flask fermentation of the engineered strain BW1 provided in Example 1 of the present invention in M9+Glu+Ile medium are shown;
[0030] Figure 4 The results of shake flask fermentation of the engineered strain BW1 provided in Example 1 of the present invention in M9+CM medium are shown;
[0031] Figure 5 The results of shake flask fermentation of the engineered strain BW1 provided in Example 1 of the present invention in M9+Glu+CM medium are shown;
[0032] Figure 6 The results of shake flask fermentation of the engineered strains BW3-BW12 provided in Example 2 of the present invention in M9+Glu+CM medium are shown. DETAILED DESCRIPTION
[0033] The technical solution of the present invention is further described in detail below through specific implementation modes, but the scope or implementation modes of the present invention are not limited.
[0034] The experimental methods used in the following examples are conventional methods unless otherwise specified. The materials and reagents used are all commercially available unless otherwise specified.
[0035] Table 1 List of Escherichia coli engineering strains constructed in various embodiments of the present invention
[0036] strains Build Process Escherichia coli BW25113 wild strain Escherichia coli BW1 Derived from a wild strain, with the gene encoding threonine dehydratase knocked out Escherichia coli BW2 Derived from BW1, plasmid overexpressing gene Escherichia coli BW3 Derived from BW1, plasmid overexpressing gene Escherichia coli BW4 Derived from BW1, plasmid overexpressing gene Escherichia coli BW5 Derived from BW1, plasmid overexpressing gene Escherichia coli BW6 Derived from BW1, plasmid overexpressing gene Escherichia coli BW7 Derived from BW1, plasmid overexpressing gene Escherichia coli BW8 Derived from BW1, plasmid overexpressing gene Escherichia coli BW9 Derived from BW1, plasmid overexpressing gene Escherichia coli BW10 Derived from BW1, plasmid overexpressing gene Escherichia coli BW11 Derived from BW1, plasmid overexpressing gene Escherichia coli BW12 Derived from BW1, plasmid overexpressing gene Escherichia coli BW13-1 Derived from BW1, plasmids overexpressing,,,,,, and genes Escherichia coli BW13-2 Derived from BW25113, plasmids overexpressing,,,,,, and genes Escherichia coli BW14 Derived from BW1, plasmids overexpressing,,,,,,, and genes Escherichia coli BW15 Derived from BW1, plasmids overexpressing,,,,,,, and genes Escherichia coli BW16 Derived from BW1, plasmids overexpressing,,,,,,, and genes Escherichia coli BW17 Derived from BW25113, plasmids overexpressing,,,,,,, and genes Escherichia coli BW18 Derived from BW25113, plasmids overexpressing,,,,,,, and genes Escherichia coli BW19 Derived from BW25113, plasmids overexpressing,,,,,,, and genes .
[0037] Example 1 Construction of an engineered Escherichia coli strain that synthesizes L-isoleucine via the methylmalate pathway
[0038] like Figure 1 As shown, the biosynthesis of L-isoleucine in Escherichia coli is mainly based on the threonine pathway, and knocking out the gene encoding threonine dehydratase (TD) ilv This will cause Escherichia coli to be unable to synthesize L-isoleucine, thereby obtaining an L-isoleucine auxotrophic Escherichia coli engineered strain BW1 (Table 1). The amino acid sequence of the threonine dehydratase is shown in SEQ ID NO.4. On this basis, the methylmalate synthase gene was overexpressed. ciA The L-isoleucine synthesis pathway based on the methylmalate pathway can be established in Escherichia coli. The specific steps are as follows:
[0039] 1. Construction of L-isoleucine auxotrophic Escherichia coli engineered strain BW1
[0040] Using Escherichia coli BW25113 as the starting strain, CRISPR-associated transposases gene editing method was used to knock out ilv Genes, specifically:
[0041] (1) Preparation of E. coli electroporation competent cells
[0042] Inoculate 300 μL of E. coli BW25113 glycerol stock into 100 mL LB medium, culture overnight at 37°C in a shaking incubator, transfer one thousandth of the inoculum into 100 mL of fresh LB medium, and culture at 37°C in a shaking incubator at 200 rpm until OD 600 Reach 0.6-0.8. Place the cultured bacterial solution on ice for 30 min, then centrifuge to collect the cells (4 ℃, 6,000 rpm, 6 min), resuspend the cells with 50 mL of pre-cooled double distilled water, centrifuge again under the same conditions to collect the cells and resuspend the cells with double distilled water. Centrifuge as above, resuspend the cells with 50 mL of pre-cooled 10% glycerol. Finally, centrifuge at 4 ℃, 6,000 rpm for 10 min, collect the cells, add 0.6 mL of pre-cooled 10% glycerol to suspend the cells, aliquot 100 μL per tube, and store in a -80℃ refrigerator.
[0043] (2) Electrotransformation of E. coli and screening of transformants
[0044] 500 ng of plasmid pTetQCas (containing QUR and cas876gene), 500 ng plasmid pRE57-tns-Ter (containing tnsABC 500 ng of pUC-spacer-ilvA were mixed and added to BW25113 electroporation competent cells. The mixture was pipetted and mixed, and then transferred to a 1 mm electroporation cuvette. The three plasmids were transformed into E. coli BW25113, then add 1 mL of sterile antibiotic-free LB liquid medium, revive at 37 ℃ for 2 h, collect the revived cells by centrifugation and spread them on LB plates containing 50 µg / mL kanamycin, 100 µg / mL ampicillin and 50 µg / mL streptomycin, and culture them in a 37 ℃ constant temperature incubator overnight. After the colonies appear, use a sterile toothpick to pick a single clone for PCR verification to confirm that all three plasmids have been successfully transformed into E. coli BW25113 cells.
[0045] (3) Construction of engineered strain BW1
[0046] The BW25113 transformant containing the three plasmids pTetQCas, pRE57-tns-Ter and pUC-spacer-ilvA was inoculated into LB liquid medium containing 50 µg / mL kanamycin, 100 µg / mL ampicillin and 50 µg / mL streptomycin, and cultured at 37 °C with shaking. 600 When the p-value reached about 0.6, 100 ng / mL of dehydrated tetracycline was added for induction to express proteins related to the CRISPR-associated transposases gene editing system, and the induction was carried out at 37°C overnight. The induced culture solution was gradiently diluted and coated on LB plates containing three antibiotics and dehydrated tetracycline inducer, and cultured at 37°C for 16 h. After the single clone appeared, clone PCR verification was performed. ilv The PCR product band of the mutant strain with successful gene knockout was 841 bp larger than that of the wild-type strain, and the positive clone was inoculated into LB liquid culture medium without antibiotics.
[0047] In order to remove the gene editing tool plasmids in the engineered strain, the positive clones (containing three gene editing plasmids) were inoculated into 50 mL LB liquid culture medium without antibiotics for subculture. The culture conditions were 45 ℃ 200rpm. After 6 subcultures, the bacterial solution was gradient diluted and coated on the non-antibiotic LB plate and cultured at 37 ℃ overnight. After the clones on the plate appeared, single colonies were randomly picked with a sterile toothpick and spotted on four LB plates without antibiotics and containing kanamycin, ampicillin and streptomycin. The single clones on the four plates corresponded to each other and were cultured at 37 ℃ overnight. Select the single clone that can only grow on the non-antibiotic LB plate and verify it again by cloning PCR ilv For gene knockout, positive clones were inoculated into 50 mL LB liquid medium to obtain the E. coli BW1 engineered strain.
[0048] 2. Construction of an engineered Escherichia coli strain BW2 that synthesizes L-isoleucine via the methylmalate pathway
[0049] Overexpression of methylmalate synthase gene based on engineered strain BW1 ciA , establish a L-isoleucine synthesis pathway based on the methylmalate pathway, specifically:
[0050] (1) Construction of cimA gene overexpression plasmid T3-cimA
[0051] Methylmalate synthase gene mutant from Methanococcus jannaschii cimA3.7 After codon optimization (its nucleotide sequence is shown in SEQ ID NO: 6), it was artificially synthesized and then used as promoter P J23100 Control its expression, and finally assemble the expression cassette into plasmid pEASY-T3 to obtain plasmid T3-cimA; the specific construction method is as follows:
[0052] Artificially synthesized cimA3.7 The gene fragment is used as a template and amplified by extension PCR J 23100 -cimA3.7 The fragment was purified by agarose gel electrophoresis and recovered, and the obtained fusion fragment was connected to the pEASY-T3 vector and transformed into E.coli Trans 1. After shaking and resuscitating the competent cells at 37 °C for 1 h, spread them on LB plates containing 100 µg / mL ampicillin and culture them for 16 h. After colonies appeared, PCR and sequencing were used to screen and verify positive clones to obtain plasmid T3-cimA.
[0053] (2) Construction of engineered strain BW2
[0054] Using the methods for preparing electrocompetent E. coli, electrocompetent transformation and transformant screening shown above, the engineered strain BW1 was prepared as electrocompetent cells, and the constructed plasmid T3-cimA was transformed into BW1 cells to obtain the engineered strain BW2.
[0055] 3. Shake flask fermentation experiments of starting strain BW25113 and engineered strains BW1 and BW2
[0056] The starting strain BW25113 and the engineered strains BW1 and BW2 were inoculated into 50 mL LB liquid medium (100 µg / mL ampicillin was added to the culture medium of BW2) and cultured overnight at 37°C and 200 rpm as seed liquid. The cell density of the seed liquid was determined and inoculated into 1 L Erlenmeyer flasks containing 200 mL fermentation medium according to a certain ratio to make the initial OD 600 The concentration was maintained at around 0.05, and the fermentation was carried out in a shaking incubator at 37 °C and 200 rpm. The fermentation medium is divided into four types, namely, fermentation medium M9+Glu: Na2HPO4 6.78 g / L, KH2PO4 3.0 g / L, NaCl 0.5 g / L, NH4Cl 1.0 g / L, MgSO40.241 g / L, CaCl2 0.011 g / L, glucose 4 g / L; fermentation medium M9+Glu+Ile: Na2HPO4 6.78 g / L, KH2PO4 3.0 g / L, NaCl 0.5 g / L, NH4Cl 1.0 g / L, MgSO4 0.241 g / L, CaCl2 0.011 g / L, glucose 4 g / L, L-isoleucine 20 mg / L; fermentation medium M9+CM: Na2HPO4 6.78 g / L, KH2PO4 3.0 g / L, NaCl 0.5 g / L, NH4Cl 1.0 g / L, MgSO4 0.241 g / L, CaCl2 0.011 g / L, methylmalic acid 4 g / L; fermentation medium M9+Glu+CM: Na2HPO4 6.78 g / L, KH2PO4 3.0 g / L, NaCl 0.5 g / L, NH4Cl 1.0 g / L, MgSO4 0.241 g / L, CaCl2 0.011 g / L, glucose 4 g / L, methylmalic acid 4 g / L. The fermentation was carried out for 48 h, and samples were taken regularly to measure the cell density (OD 600 ) and the glucose and methylmalic acid content in the fermentation broth. Figure 2 As shown, the wild-type BW25113 strain grew well in the basic medium (M9+Glu) with glucose as the sole carbon source, while the knockout ilvThe engineered strain BW1 could not grow normally, but after adding a certain amount of isoleucine (M9+Glu+Ile) to the culture medium, BW1 resumed normal growth and glucose consumption ( Figure 3 ), indicating that BW1 is an isoleucine auxotrophic strain. Overexpression in the BW1 strain ciA The BW2 engineered bacteria obtained by the gene can grow normally in the basic medium (M9+Glu) without isoleucine supplementation ( Figure 2 ), explaining the expression ciA The gene can establish an L-isoleucine synthesis pathway based on the methylmalate pathway in Escherichia coli, so that the growth of the BW2 strain no longer requires additional L-isoleucine.
[0057] When the BW1 engineered strain was cultured in a basal medium (M9+CM) with methylmalate as the sole carbon source, the BW1 strain grew slowly after a growth lag period of about 10 hours, and the methylmalate was also partially consumed, indicating that methylmalate can be used as a carbon source to supply the growth of the strain and can also be used as a precursor to synthesize L-isoleucine through the methylmalate pathway ( Figure 4 When the fermentation medium was M9+Glu+CM, the growth of the BW1 strain was greatly inhibited, and neither glucose nor methylmalic acid was consumed ( Figure 5 ). The above results indicate that due to the carbon metabolism inhibition effect, when glucose is present in the culture medium, methylmalic acid cannot be transported into the cell for metabolism, which results in the inability of the BW1 strain to grow in the M9+Glu+CM medium.
[0058] Example 2 Removal of the inhibitory effect of glucose on methylmalate utilization by expressing methylmalate transporter
[0059] Expression in engineered strain BW1 cells ciA The gene can make the strain grow normally in M9+Glu basal medium, indicating that methylmalate synthesized by CimA can be normally utilized in the cell and synthesize L-isoleucine, while when methylmalate is added outside the BW1 cell, it will be inhibited by glucose and unable to grow. This shows that the inhibitory effect of glucose on the utilization of methylmalate is mainly reflected in the inhibition of the absorption of methylmalate from the extracellular into the cell. Overexpression of methylmalate transporter can relieve the inhibitory effect of glucose on the utilization of methylmalate. The specific steps are as follows:
[0060] 1. Construction of the methylmalate transporter gene overexpression engineered strain BW3-BW12
[0061] Based on the engineered strain BW1, the methylmalate transporter gene was overexpressed to relieve the inhibitory effect of glucose on the utilization of methylmalate. Specifically:
[0062] (1) Construction of methylmalate transporter gene overexpression plasmid
[0063] Currently, there are few reports on methylmalate transporters. In this study, we investigated whether transporters of C3-C7 di- and tri-carboxylic acids would have transport activity for methylmalate. Ten known di- and tri-carboxylic acid transporters, including DcuD, DauA, DcuA, SatP (whose amino acid sequence is shown in SEQ ID NO: 15), TtdT (whose amino acid sequence is shown in SEQ ID NO: 16), DctA (whose amino acid sequence is shown in SEQ ID NO: 17), DcuC (whose amino acid sequence is shown in SEQ ID NO: 18), CitT (whose amino acid sequence is shown in SEQ ID NO: 19), DcuB (whose amino acid sequence is shown in SEQ ID NO: 20) and YbhI (whose amino acid sequence is shown in SEQ ID NO: 21), were overexpressed and expressed using promoter P J23100 The corresponding gene fragments were amplified by PCR using the genome of Escherichia coli BW25113 as a template, and the expression cassettes of the 10 transporter genes were installed on the plasmid pEASY-T3 using the plasmid construction method shown in Example 1 to obtain plasmid T3- Dq 、T3- D 、T3- oeLh 、T3- SatP 、T3- TxD 、T3- DctA 、T3- C 、T3- CitT 、T3- ikB and T3- Yj Y .
[0064] (2) Construction of engineered strains BW3-BW12
[0065] Using the preparation of Escherichia coli electroporation competent cells, electroporation and transformant screening methods shown in Example 1, the engineering strain BW1 was prepared as electroporation competent cells, and the constructed plasmid T3- Dq 、T3- D 、T3- oeLh 、T3- SatP 、T3- TxD 、T3- DctA 、T3- C 、T3- CitT 、T3- ikB and T3- Yj Y The genes were transformed into BW1 cells respectively to obtain engineered strains BW3-BW12 (Table 1).
[0066] 2. Shake flask fermentation experiment of engineered strains BW3-BW12
[0067] The shake flask fermentation method shown in Example 1 was used to carry out the fermentation experiment of the engineered strain BW3-BW12 using the fermentation medium M9+Glu+CM. The fermentation was carried out for a total of 48 h, and samples were taken at regular intervals to measure the cell density (OD 600 ).like Figure 6 As shown, the engineered strains BW3-BW12 all grew to varying degrees at 48 h, while the corresponding BW1 strain could not grow in M9+Glu+CM medium ( Figure 5 ), indicating that the 10 overexpressed dibasic or tribasic carboxylic acid transporters can relieve the inhibitory effect of glucose on methylmalate utilization to a certain extent. Among them, Dq , D and oeLh The three transporters have a better absorption effect on methylmalate, which can accumulate the cell biomass in a shorter time.
[0068] Example 3 Improving L-isoleucine synthesis capacity by strengthening the methylmalate pathway
[0069] Example 1 demonstrates that overexpression ciA The gene can establish an L-isoleucine synthesis pathway based on the methylmalate pathway in Escherichia coli. Therefore, in order to further improve the carbon flux of L-isoleucine synthesis, in addition to ciA In addition to the gene, other methylmalate pathway-related genes and methylmalate absorption protein genes were further overexpressed to improve the L-isoleucine synthesis capacity of the engineered strain. In addition to the methylmalate synthase CimA, the methylmalate pathway-related catalytic enzymes also include isopropylmalate isomerase (IPMI), 3-isopropylmalate dehydrogenase (IPMD), acetohydroxyacid synthase (AHAS), acetohydroxyacid reductoisomerase (AHAIR), dihydroxyacid dehydratase (DHAD), branched-chain amino acid aminotransferase (BCAT), leucine dehydrogenase (LeuDH) and valine dehydrogenase (ValDH). Among them, there are many types of AHAS, including IlvIH, IlvBN and IlvGM, all of which catalyze the same step reaction ( Figure 1 ); BCAT, LeuDH and ValDH are three enzymes that use glutamate (BCAT) or NH4 + (LeuDH and ValDH) act as amino donors to catalyze the final step of L-isoleucine synthesis ( Figure 1 ). Therefore, this application selects to overexpress Escherichia coli itself. IPMI ( eu )、 IPMD ( leuB )、 AHAS ( iV )、 AHAIR ( ilvC )、 DHAD ( ilvD )and BCAT ( ilvE ) gene to enhance the methylmalate pathway. Wherein, LeuCD includes subunits LeuC and LeuD, LeuC, whose amino acid sequence is shown in SEQ ID NO: 7; LeuD, whose amino acid sequence is shown in SEQ ID NO: 8; LeuB, whose amino acid sequence is shown in SEQ ID NO: 9; IlvIH includes subunits Ilv and subunit IlvH, whose amino acid sequence of IlvI is shown in SEQ ID NO: 10; the amino acid sequence of IlvH is shown in SEQ ID NO: 11; IlvC, whose amino acid sequence is shown in SEQ ID NO: 12; IlvD, whose amino acid sequence is shown in SEQ ID NO: 13; IlvE, whose amino acid sequence is shown in SEQ ID NO: 14.
[0070] The specific steps are as follows:
[0071] 1. Construction of methylmalate pathway-enhanced strains BW13-1 and BW13-2
[0072] Based on the engineered strain BW1 and the wild strain BW25113, the genes related to the methylmalate pathway were overexpressed to increase the carbon flux of L-isoleucine synthesis, specifically:
[0073] (1) Construction of plasmids for overexpression of genes related to the methylmalate pathway
[0074] like Figure 1 As shown, except ciA In addition to genes, genes related to the methylmalate pathway include IPMI ( eu )、 IPMD ( leuB )、 AHAS ( iV )、 AHAIR ( ilvC )、 DHAD ( ilvD )and BCAT ( ilvE) genes, so CimA3.7 and E. coli-derived LeuC (its amino acid sequence is shown in SEQ ID NO: 7), LeuD (its amino acid sequence is shown in SEQ ID NO: 8), LeuB (its amino acid sequence is shown in SEQ ID NO: 9), IlvI (its amino acid sequence is shown in SEQ ID NO: 10), IlvH (its amino acid sequence is shown in SEQ ID NO: 11), IlvC (its amino acid sequence is shown in SEQ ID NO: 12), IlvD (its amino acid sequence is shown in SEQ ID NO: 13) and IlvE (its amino acid sequence is shown in SEQ ID NO: 14) enzyme proteins were overexpressed, and promoter P was used to generate the 3D-type 237 gene. J23100 The corresponding gene fragments were amplified by PCR using the genome of Escherichia coli BW25113 as a template, and the plasmid construction method shown in Example 1 was used to construct the corresponding gene fragments. ciA , euC , LqCy and leuB The expression cassette was assembled into plasmid pRSFDuet-1 to obtain plasmid pRSFDuet-1- ciA - euC - LqCy - leuB ; iV , ilvC , ilvD and ilvE The expression cassette was assembled into the plasmid pETDuet-1 to obtain the plasmid pETDuet-1- iV - ilvC - ilvD - ilvE .
[0075] (2) Construction of engineered strains BW13-1 and BW13-2
[0076] Using the preparation of Escherichia coli electroporation competent cells, electroporation and transformant screening methods shown in Example 1, the engineered strain BW1 and the wild strain BW25113 were prepared as electroporation competent cells, and the constructed plasmid pRSFDuet-1- ciA - euC - LqCy - leuB and pETDuet-1- iV - ilvC - ilvD - ilvEThe transformed strains were transformed into BW1 and BW25113 cells, and the transformants were selected using LB plates containing 50 µg / mL kanamycin and 100 µg / mL ampicillin. The transformed strains were verified by clonal PCR, and finally the engineered strains BW13-1 and BW13-2 were obtained (Table 1).
[0077] 2. Shake flask fermentation experiments of wild strain BW25113, engineered strains BW2, BW13-1 and BW13-2
[0078] The wild strain BW25113, engineered strain BW2 (added with 100 µg / mL ampicillin), BW13-1 (added with 50 µg / mL kanamycin and 100 µg / mL ampicillin), and BW13-2 (added with 50 µg / mL kanamycin and 100 µg / mL ampicillin) were inoculated into 50 mL LB liquid medium and cultured overnight at 37 °C and 200 rpm as seed liquid. The cell density of the seed liquid was determined and inoculated into a 1 L Erlenmeyer flask containing 200 mL fermentation medium according to a certain ratio to make the initial OD 600 The fermentation medium is kept at about 0.2, and the fermentation is carried out at 37 ° C and 200 rpm. The fermentation medium is: glucose 20 g / L, KH2PO4 13.3 g / L, (NH4)2HPO4 4 g / L, MgSO4·7H2O 1.2 g / L, citric acid monohydrate 1.7 g / L, EDTA·2Na 1.68 mg / L, CoCl2·6H2O 0.5 mg / L, MnCl2·4H2O 3 mg / L, CuCl2·2H2O 0.3 mg / L, H3BO3 0.6 mg / L, Na2MoO4·2H2O 0.5 mg / L, Zn(CH3COO)2·2H2O 2.6 mg / L, ferric citrate 20 mg / L, VB1 0.9 mg / L. The fermentation was carried out for 48 h. At the end of the fermentation, samples were taken to determine the contents of methylmalic acid and isoleucine in the fermentation broth. The results are shown in Table 2.
[0079] Table 2 Shake flask fermentation results of wild strain BW25113, engineered strains BW2, BW13-1 and BW13-2
[0080] strains Methylmalic acid (g / L) L-Isoleucine (g / L) BW25113 Not Detected Not detected BW2 3.26 0.034 BW13-1 2.80 0.076 BW13-2 2.95 0.079 .
[0081] As shown in Table 2 above, the L-isoleucine produced by the wild strain BW25113 during the fermentation process can only meet the growth needs of the strain, and no accumulation of L-isoleucine was detected in the fermentation broth. In addition, BW25113 does not have enzymes related to methylmalate synthesis, so no accumulation of methylmalate was detected in the fermentation broth. cimA The engineered strain BW2 produced a large amount of methylmalic acid, reaching 3.26 g / L, while the yield of L-isoleucine was low, only 0.034 g / L. cimA After further overexpression of other genes related to the methylmalate pathway on the basis of the gene, the L-isoleucine production of the engineered strains BW13-1 and BW13-2 was improved to a certain extent, but it was still at a low level, only 0.076 and 0.079 g / L, while a large amount of methylmalate (2.80 and 2.95 g / L) was still not converted into L-isoleucine. At the same time, the fermentation results of the wild strain BW25113 and the engineered strains BW13-1 and BW13-2 showed that BW25113 itself ilvA The gene had little effect on the accumulation of L-isoleucine in the fermentation broth.
[0082] Example 4 Improving the L-isoleucine synthesis capacity based on the methylmalate pathway by expressing the methylmalate transporter
[0083] As shown in Example 1, when glucose is present in the culture medium, extracellular methylmalic acid cannot be utilized by E. coli. The results of Example 3 show that E. coli expressing cimA The large amount of methylmalate produced after the gene is overexpressed will be quickly excreted by the cells, while the extracellular methylmalate can no longer be transported into the cells, resulting in a lack of precursors for subsequent isoleucine synthesis, leading to low L-isoleucine production levels. As shown in Example 2, the inhibitory effect of glucose on the utilization of methylmalate can be relieved by expressing the methylmalate transporter, so overexpressing the methylmalate transporter gene DcuD , DauA and DcuA The method can effectively improve the efficiency of L-isoleucine synthesis based on the methylmalate pathway. The specific steps are as follows.
[0084] 1. Construction of the methylmalate transporter gene DcuD, DauA and DcuA overexpression engineered strains BW14-BW19
[0085] Based on the engineered strains BW13-1 and BW13-2, the methylmalate transporter was further overexpressed to improve the efficiency of L-isoleucine synthesis, specifically:
[0086] (1) Construction of methylmalate transporter gene overexpression plasmid
[0087] As shown in Example 2, the methylmalate transporter gene DcuD , DauA and DcuA It can more effectively relieve the inhibitory effect of glucose on the utilization of methylmalate. Therefore, we chose to overexpress these three genes and use the promoter P J23100 The corresponding gene fragments were amplified by PCR using the genome of Escherichia coli BW25113 as a template, and the plasmid construction method shown in Example 1 was used to construct the DcuD , DauA and DcuA The expression cassettes were assembled into plasmid pETDuet-1- ilvIH - ilvC - ilvD - ilvE , and obtain the plasmid pETDuet-1- ilvIH - ilvC - ilvD - ilvE - DcuD 、pETDuet-1- ilvIH - ilvC - ilvD - ilvE - DauA and pETDuet-1- ilvIH - ilvC - ilvD - ilvE - DcuA .
[0088] (2) Construction of engineered strains BW14-BW19
[0089] Using the preparation of Escherichia coli electroporation competent cells, electroporation and transformant screening methods shown in Example 1, the engineered strain BW1 and the wild strain BW25113 were prepared as electroporation competent cells, and the constructed plasmid pRSFDuet-1- cimA - leuC - leuD - leuB The strain BW1 (pRSFDuet-1- cimA - leuC - leuD - leuB ) and BW25113 (pRSFDuet-1- cimA - leuC - leuD - leuB). Using the same electroporation competent medium preparation and electroporation method, the engineered strain BW1 (pRSFDuet-1- cimA - leuC - leuD - leuB ) and BW25113 (pRSFDuet-1- cimA - leuC - leuD - leuB ) were prepared as electroporation competent cells, and the constructed plasmid pETDuet-1- ilvIH - ilvC - ilvD - ilvE - DcuD 、pETDuet-1- ilvIH - ilvC - ilvD - ilvE - DauA and pETDuet-1- ilvIH - ilvC - ilvD - ilvE - DcuA Transformed into BW1 (pRSFDuet-1- cimA - leuC - leuD - leuB ) and BW25113 (pRSFDuet-1- cimA - leuC - leuD - leuB ) engineered strains, and transformants were selected using LB plates containing 50 µg / mL kanamycin and 100 µg / mL ampicillin. The transformants were verified by clonal PCR, and finally the engineered strains BW14-BW19 were obtained (Table 1).
[0090] 2. Shake flask fermentation experiment of engineered strains BW14-BW19
[0091] The fermentation experiment of the engineered strains BW14-BW19 was carried out using the shake flask fermentation method and fermentation medium shown in Example 3. The fermentation was carried out for a total of 48 hours. At the end of the fermentation, samples were taken to measure the contents of methylmalic acid and isoleucine in the fermentation broth. The results are shown in Table 3.
[0092] Table 3 Shake flask fermentation results of engineered strains BW14-BW19
[0093] Strain Methylmalic acid (g / L) L-Isoleucine (g / L) BW14 0.64 0.43 BW15 0.76 0.39 BW16 0.95 0.32 BW17 0.65 0.45 BW18 0.80 0.39 BW19 0.99 0.35 .
[0094] Combined with the data disclosed in Table 2 and Table 3, the methylmalate transporter gene was further overexpressed on the basis of the engineered strain BW13-1. DcuD , DauA and DcuA After the fermentation, the utilization rate of methylmalic acid was significantly improved. The yields of methylmalic acid in the fermentation broth of engineered strains BW14, BW15 and BW16 were 0.64, 0.76 and 0.95 g / L, respectively, which were reduced by about 77.1%, 72.9% and 66.1% compared with BW13-1. In addition, the synthesis efficiency of L-isoleucine was also greatly improved. The yields of L-isoleucine in the fermentation broth of engineered strains BW14, BW15 and BW16 reached 0.43, 0.39 and 0.32 g / L, respectively, which were increased by about 4.7, 4.1 and 3.2 times compared with BW13-1. The fermentation results of engineered strains BW17, BW18, BW19 and BW13-2 were similar to the above results.
[0095] The above results indicate that the methylmalate transporter provided by the present invention can significantly improve the utilization efficiency of methylmalate and the L-isoleucine synthesis capacity based on the methylmalate pathway.
[0096] The above embodiments are only used to understand the technical solution of the present application and do not limit the protection scope of the present application.
Claims
1. A method for increasing the yield of synthetic L-isoleucine based on the methylmalate pathway, characterized in that: The method comprises the following steps: overexpressing a methylmalate synthase gene in Escherichia coli; and Expressing carboxylic acid transporter DcuD, DauA or DcuA encoding gene, wherein the amino acid sequences of the carboxylic acid transporter DcuD, DauA and DcuA are shown as SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively.
2. The method for increasing the yield of synthetic L-isoleucine based on the methylmalate pathway according to claim 1, characterized in that: The amino acid sequence of the methylmalate synthase is shown in SEQ ID NO.
5.
3. The method for increasing the yield of synthetic L-isoleucine based on the methylmalate pathway according to claim 2, characterized in that: The nucleotide sequence of the methylmalate synthase gene is shown in SEQ ID NO:
6.
4. The method for increasing the yield of synthetic L-isoleucine based on the methylmalate pathway according to claim 1, characterized in that: The method further comprises the step of expressing in E. coli a gene encoding an enzyme associated with the methylmalate pathway, wherein the enzyme associated with the methylmalate pathway comprises one or more of the following enzymes: Isopropylmalate isomerase, 3-isopropylmalate dehydrogenase, acetohydroxyacid synthase, acetohydroxyacid reductoisomerase, dihydroxyacid dehydratase, branched-chain amino acid aminotransferase, leucine dehydrogenase or valine dehydrogenase.
5. The method for increasing the yield of synthetic L-isoleucine based on the methylmalate pathway according to claim 4, characterized in that: The isopropylmalate isomerase comprises isopropylmalate isomerase IPMI or isopropylmalate isomerase LeuCD, wherein the isopropylmalate isomerase LeuCD comprises a LeuC subunit and a LeuD subunit; The 3-isopropylmalate dehydrogenase includes 3-isopropylmalate dehydrogenase IPMD or 3-isopropylmalate dehydrogenase LeuB; The acetohydroxyacid synthase includes acetohydroxyacid synthase AHAS or acetohydroxyacid synthase IlvIH; The acetohydroxy acid reductoisomerase includes acetohydroxy acid reductoisomerase AHAIR or acetohydroxy acid reductoisomerase IlvC; The dihydroxy-acid dehydratase comprises dihydroxy-acid dehydratase DHAD or dihydroxy-acid dehydratase IlvD; The branched-chain amino acid aminotransferase includes dihydroxyacid dehydratase BCAT or dihydroxyacid dehydratase IlvE; The leucine dehydrogenase includes a subunit LeuD and a subunit LeuH.
6. An engineered strain for synthesizing L-isoleucine based on the methylmalate pathway, characterized in that: The engineered strain is an Escherichia coli strain obtained by the following transformations: Overexpression of methylmalate synthase gene; Expressing carboxylic acid transporter DcuD, DauA or DcuA encoding gene, wherein the amino acid sequences of the carboxylic acid transporter DcuD, DauA and DcuA are shown as SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively.
7. The engineered strain for synthesizing L-isoleucine based on the methylmalate pathway according to claim 6, characterized in that: The amino acid sequence of the methylmalate synthase is shown in SEQ ID NO.
5.
8. The engineered strain for synthesizing L-isoleucine based on the methylmalate pathway according to claim 6, characterized in that: The engineered strain further expresses genes encoding enzymes related to the methylmalate pathway, and the methylmalate pathway related enzymes include one or more of the following enzymes: Isopropylmalate isomerase, 3-isopropylmalate dehydrogenase, acetohydroxyacid synthase, acetohydroxyacid reductoisomerase, dihydroxyacid dehydratase, branched-chain amino acid aminotransferase, leucine dehydrogenase or valine dehydrogenase.
9. The engineered strain for synthesizing L-isoleucine based on the methylmalate pathway according to claim 8, characterized in that: The isopropylmalate isomerase comprises isopropylmalate isomerase IPMI or isopropylmalate isomerase LeuCD, wherein the isopropylmalate isomerase LeuCD comprises a LeuC subunit and a LeuD subunit; The 3-isopropylmalate dehydrogenase includes 3-isopropylmalate dehydrogenase IPMD or 3-isopropylmalate dehydrogenase LeuB; The acetohydroxyacid synthase includes acetohydroxyacid synthase AHAS or acetohydroxyacid synthase IlvIH; The acetohydroxy acid reductoisomerase includes acetohydroxy acid reductoisomerase AHAIR or acetohydroxy acid reductoisomerase IlvC; The dihydroxy-acid dehydratase comprises dihydroxy-acid dehydratase DHAD or dihydroxy-acid dehydratase IlvD; The branched-chain amino acid aminotransferase includes dihydroxyacid dehydratase BCAT or dihydroxyacid dehydratase IlvE; The leucine dehydrogenase includes a subunit LeuD and a subunit LeuH.
10. A method for preparing L-isoleucine by fermentation, characterized in that: The method comprises the step of preparing L-isoleucine by fermenting the engineered strain for synthesizing L-isoleucine based on the methylmalate pathway according to claim 6.
